Comparative real-world effectiveness and safety of benralizumab and two mepolizumab dosing regimens in eosinophilic granulomatosis with polyangiitis: a 24-month prospective single-center cohort study - Takeaways - MDSpire

Comparative real-world effectiveness and safety of benralizumab and two mepolizumab dosing regimens in eosinophilic granulomatosis with polyangiitis: a 24-month prospective single-center cohort study

  • By

  • Marta Codirenzi

  • Federica Davanzo

  • Luca Iorio

  • Eleonora Fiorin

  • Gabriella Guarnieri

  • Fulvia Chieco Bianchi

  • Alessia Achille

  • Maria Rita Marchi

  • Andrea Vianello

  • Andrea Doria

  • Roberta Ramonda

  • Roberto Padoan

  • June 15, 2026

  • 0 min

Share

  • 1

    The study evaluated the effectiveness of benralizumab and two mepolizumab dosing strategies in patients with eosinophilic granulomatosis with polyangiitis.

  • 2

    After 24 months, remission rates were 73.7% for benralizumab and 81.0% for mepolizumab 300 mg, with no significant differences between the treatments.

  • 3

    Glucocorticoid-free status improved significantly, reaching 63.2% with benralizumab and 85.7% with mepolizumab 300 mg at 24 months.

  • 4

    Eosinophil counts decreased markedly, with near-complete suppression observed in the benralizumab group, indicating effective eosinophil-targeted therapy.

  • 5

    The study concluded that anti–IL-5/IL-5R biologics are effective and well tolerated, supporting individualized treatment strategies in EGPA.

Original Source(s)

Comparative real-world effectiveness and safety of benralizumab and two mepolizumab dosing regimens in eosinophilic granulomatosis with polyangiitis: a 24-month prospective single-center cohort study

  • by Marta Codirenzi, Federica Davanzo, Luca Iorio, Eleonora Fiorin, Gabriella Guarnieri, Fulvia Chieco Bianchi, Alessia Achille, Maria Rita Marchi, Andrea Vianello, Andrea Doria, Roberta Ramonda, Roberto Padoan

  • June 15, 2026

Related Content

Systemic lupus erythematosus–driven accelerated atherosclerosis: the immune–metabolic–vascular axis and therapeutic implications

Hair Repigmentation Reported With Baricitinib in Canities Subita

A single case suggests a possible benefit, but confounding factors and the off-label setting temper the conclusions.

AKT-mediated phosphorylation of ZDHHC5 promotes NOD1 palmitoylation and innate immune signaling